Alvotech (ALVO) Total Non-Current Liabilities (2020 - 2026)
Alvotech (ALVO) posted Total Non-Current Liabilities of $1.4 billion for Q1 2026, down 1.62% on a QoQ basis from $1.5 billion in Q4 2025, and little changed year-over-year from $1.4 billion in Q1 2025.
Alvotech (ALVO) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Alvotech's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- Quarterly Total Non-Current Liabilities changed 0.2% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (changed 0.2% YoY) and the FY2025 annual result came in at $1.5 billion, up 1.86% from the prior year.
- Total Non-Current Liabilities was $1.4 billion for Q1 2026 at Alvotech, down from $1.5 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.6 billion in Q4 2023 and bottomed at $471.9 million in Q2 2024.
- A 5-year average of $1.3 billion and a median of $1.4 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities plunged 59.58% — and 2025, when it soared 172.57%.
- Alvotech's Total Non-Current Liabilities stood at $1.2 billion in 2022, then surged by 32.32% to $1.6 billion in 2023, then decreased by 11.15% to $1.4 billion in 2024, then increased by 1.86% to $1.5 billion in 2025, then declined by 1.62% to $1.4 billion in 2026.
- Business Quant data shows ALVO's Total Non-Current Liabilities at $1.4 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | 1.44 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.44 Bn |
| Dec 31, 2025 | 1.47 Bn |
| Sep 30, 2025 | 1.44 Bn |
| Jun 30, 2025 | 1.29 Bn |
| Mar 31, 2025 | 1.44 Bn |
| Dec 31, 2024 | 1.44 Bn |
| Sep 30, 2024 | 1.42 Bn |
| Jun 30, 2024 | 471.93 Mn |
| Mar 31, 2024 | 1.47 Bn |
| Dec 31, 2023 | 1.62 Bn |
| Jun 30, 2023 | 1.17 Bn |
| Mar 31, 2023 | 1.39 Bn |
| Dec 31, 2022 | 1.23 Bn |
| Jun 30, 2022 | 792.93 Mn |
| Dec 31, 2021 | 621.75 Mn |
| Dec 31, 2020 | 1.29 Bn |